A Phase 1, Double-blind, Placebo-controlled, Randomized, Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GSK2336805 (Part 1), Followed by an Open-label, Randomized, 4-way Crossover Study to Evaluate Short-term Safety, Tolerability and Pharmacokinetics of the Co-administration of TMC435 and GSK2336805 at Steady-state (Part 2), in Healthy Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 25 Jul 2014
At a glance
- Drugs JNJ 56914845 (Primary) ; Simeprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Janssen R&D Ireland
- 16 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrial.gov record.
- 15 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrial.gov.
- 03 Jan 2014 New trial record